Antiarrhythmic drugs 2013: State of the art topical collection on invasive electrophysiology and pacing

Current Cardiology Reports

Volumn 15, Issue 10, 2013, Pages

  Kumar, Kapil ^a   Zimetbaum, Peter J ^b  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Amiodarone analogues; Antiarrhythmic drugs; Atrial fibrillation; Azimilide; Budiodarone; Celivarone; Dronedarone; Drug synergy; Ivabradine; Ranolazine; Ventricular tachycardia; Vernakalant

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BUDIODARONE; CELIVARONE; DRONEDARONE; IVABRADINE; PLACEBO; RANOLAZINE; SOTALOL; VERNAKALANT;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ARTICLE; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LIVER DISEASE; LOW DRUG DOSE; LUNG DISEASE; NONHUMAN; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; SIDE EFFECT; STABLE ANGINA PECTORIS; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ARRHYTHMIAS, CARDIAC; DRUG DEVELOPMENT; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DRUG DISCOVERY; DRUG SYNERGISM; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84896591118     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-013-0410-2     Document Type: Article

References (59)

1. • LafAuente-Lafuente C, Longas-Tejero MA, Bergmann JF, et al. Cochrane review 2012 antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5:CD005049. Excellent review of current clinically available antiarrhythmic drugs and their limitations.
2. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33.
3. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40. (Pubitemid 35417774)
4. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-77. (Pubitemid 351860859)
5. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-99. (Pubitemid 47367078)
6. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety ofdronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.
7. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-78.
8. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-87. (Pubitemid 351860860)
9. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268-76.
10. Morey TE, Seubert CN, Raatkainen MJP, et al. Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol Exp Ther. 2000;297:260-6. (Pubitemid 32242586)
11. Arya A, Silberbauer J, Teichman SL, et al. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace. 2009;11:458-64.
12. Ezekowitz MD, Nagarakanti R, Lubinski A, et al. A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012;34:1-9.
13. Gautier P, Guillemare E, Djandjighian L, et al. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol. 2004;44:244-57. (Pubitemid 38982169)
14. Gojkovic O, Aliot EM, Capucci A, et al. Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverterdefibrillator interventions. Hear Rhythm. 2012;9:217-24.
15. Kowey PR, Crijns HJGM, Aliot EM, et al. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter- defibrillator interventions or death: the ALPHEE Study. Circulation. 2011;124:2649-60.
16. Khitri AR, Aliot EM, Capucci A, et al. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. J Cardiovasc Electrophysiol. 2012;23:462-47.
17. Wettwer E, Hala O, Christ T, et al. Role of IKur in controlling action potential shape and contractility in the human atrium. Influence of chronic atrial fibrillation. Circulation. 2004;110:2299-306. (Pubitemid 39407330)
18. Voigt N et al. Left to right atrial inward-rectifier potassium current gradients in patient was paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:472-80.
19. Burashnikov A, Pourrier M, Gibson JK, et al. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol. 2012;5(2):400-8.
20. Naccarelli GV, Wolbrette DL, Samii S, et al. Vernakalant: pharmacology electrophysiology, safety and efficacy. Drugs Today (Barc). 2008;44:325-9.
21. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518-25. (Pubitemid 351440640)
22. Roy D, Pratt C, Juul-Moller S, et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial [abstract]. J Am Coll Cardiol. 2006;47:10A.
23. Kowey PR, Roy D, Pratt CM, et al. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery. Circulation. 2007:114.
24. Wettwer E, Christ T, Endig S, et al. The new antiarrhythmic drug Vernakalant: ex-vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Cardiovasc Res. 2013;98(1):145-54.
25. Lynch Jr JJ, Regan CP, Beatch GN, et al. Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues. J Cardiovasc Pharmacol. 2013;61(3):226-32.
26. Cheng JWM, Rybak I. Pharmacotherapy options in atrial fibrillation: focus on vernakalant. Clin Med Therapeutics. 2009;1:215-30.
27. Torp-Pedersen C, Raev DH, Dickinson G, et al. A randomized, placebo-controlled study of vernakalant (Oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol. 2011;4:637-43.
28. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775-83. (Pubitemid 46658646)
29. Bunch TJ, Mahapatra S, Murdock DK, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34:1600-6.
30. Murdock DK, Kaliebe JW, Overton N. Ranolazine-induced suppression of ventricular tachycardia in a patient with non-ischemic cardiomyopathy: a case report. Pacing Clin Electrophysiol. 2008;31:765-8. (Pubitemid 351749321)
31. Kaliebe JW, Murdock DK. Suppression of non-sustained ventricular tachycardia with ranolazine: a case report. WMJ. 2009;108:373-5.
32. Nanda S, Levin V, Martinez MW, et al. Ranolazine - treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy. Pacing Clin Electrophysiol. 2010;33:e119-120.
33. Murdock DK, Kaliebe JW. Suppression of frequent ventricular ectopy in a patient with hypertrophic heart disease with ranolazine: a case report. Indian Pacing Electrophysiol J. 2011;11:84-8.
34. Tagarakis GI, Aidonidis I, Daskalopoulou SS, et al. Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery. Curr Vasc Pharmacol. 2012 Nov 7. [Epub ahead of print].
35. Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011;108:673-6.
36. Murdock DK, Kersten M, Kaliebe J, et al. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible pill in the pocket approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009;9:260-7.
37. Murdock DK, Kaliebe J, Larrain G. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series. Pacing Clin Electrophysiol. 2012;35:302-7.
38. Murdock DK, Overton N, Kersten M, et al. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008;8:175-81.
39. Burashnikov A, Antzelevitch C. Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther. 2013;27:79-89.
40. Fredj S, Sampson KJ, Liu H, et al. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006;148:16-24. (Pubitemid 43675596)
41. Beyder A, Strege PR, Reyes S, et al. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel NaV1.5: a novel mechanism of drug action. Circulation. 2012;125:2698-706.
42. Parikh A, Mantravadi R, Kozhevnikov D, et al. Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. Hear Rhythm. 2012;9:953-60.
43. Page RL, Connolly SJ, Wilkinson WE, et al. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. Am Heart J. 2002;143:643-9. (Pubitemid 34454697)
44. Page RL, Tilsch TW, Connolly SJ, et al. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation. 2003;107:1141-5. (Pubitemid 36300748)
45. Lombardi F, Borggrefe M, Ruzyllo W, et al. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide- cardiOversion MaintEnance Trial-II) trial. Eur Heart J. 2006;27:2224-31. (Pubitemid 44412838)
46. Kerr CR, Connolly SJ, Kowey P, et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol. 2006;98:215-8. (Pubitemid 43975503)
47. Dorian P, Borggrefe M, Al-Khalidi HR, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation. 2004;110:3646-54. (Pubitemid 39665252)
48. Conway E, Musco S, Kowey PR. New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Am J Cardiol. 2008;102(suppl):12H-9H.
49. Dorian P, Al-Khalidi HR, Hohnloser SH, et al. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. J Am Coll Cardiol. 2008;52:1076-83.
50. Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiologic effects and safety. Drug Saf. 2008;31:95-107. (Pubitemid 351175614)
51. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:807-16.
52. Borer JS, Bohm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study. Eur Heart J. 2012;33:2813-20.
53. Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivavradine in patients with inappropriate sinus tachycardia. J Am Coll Cardiol. 2012;60:1323-9.
54. McDonald C, Frith J, Newton. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011;13:427-30.
55. Sutton R, Salukhe T. Ivabradine in the treatment of orthostatic intolerance. Europace. 2011;13:306-7.
56. Bohora S, Lokhandwala Y, Parekh P, et al. Reveral fo tachycardiomyopathy due to left atrial tachycardia by ivabradine. J Cardiovasc Electrophysiol. 2011;22:340-2.
57. • Burashnikov A, Sicouri S, Di Diego JM, et al. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56:1216-24. First study to demonstrate synergistic effects between ranolazine and dronedarone in vitro.
58. Verrier RL, Pagotto VPF, Kanas AF, et al. Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. Hear Rhythm. 2013;10:121-7.
59. Fragakis N, Koskinas KC, Katritsis DG, et al. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012;110:673-7.